Vicore Pharma has designed, synthesised and patented a unique collection of small non-peptide molecules suitable for development into a clinically important and commercially attractive new class of drugs.
These molecules exert their effect within the Renin Angiotensin System (RAS). More precisely, they stimulate the AT2 receptor (so-called AT2 agonism), which is a unique approach to modulation of the system. The primary candidate drug, "Compound 21" or "C21", emerged from an extensive medicinal chemistry program, chosen from a large number of patent protected AT2 agonists.
The molecules are all highly selective agonists of the AT2 receptor. Such stimulation is a much coveted pharmaceutical technique which has not been possible until now.
In in vitro pharmacokinetic studies, scale-up of the chemical synthesis and preparation for regulatory safety (toxicity) studies has been performed. The chemical and pharmaceutical (including pharmacokinetic) properties of C21 render it well-suited for both oral and intravenous administration.
